01—Abstract
Summary
Summary of the 8-K filed July 31, 2025. Cited figures are marked; the original filing is the authoritative source.
CVS Health reported second-quarter 2025 results on July 31, 2025, with total revenues up 8.4% year over year to $98.9 billion, but GAAP diluted EPS fell to $0.80a from $1.41 because of $833 million in legacy litigation charges tied to two court decisions over past business practices (an Omnicare False Claims Act verdict and a PBM reporting case).
Adjusted EPS was roughly flat at $1.81b versus $1.83, and adjusted operating income rose 1.7% to $3.81 billion, driven by Health Care Benefits and Pharmacy & Consumer Wellness, partly offset by a 17.8% decline in Health Services. Operating cash flow for the six months was $6.5 billion, down from $8.0 billion a year earlier. Management raised its full-year 2025 Adjusted EPS guidance to $6.30–$6.40 (from $6.00–$6.20) and raised operating cash flow guidance to at least $7.5 billion (from about $7.0 billion), while lowering GAAP diluted EPS guidance to $3.84–$3.94 (from $4.23–$4.43) to reflect the litigation charges.
Within Health Care Benefits, the medical benefit ratio rose to 89.9% from 89.6%, pressured by a $471 millionc premium deficiency reserve in Group Medicare Advantage, while the individual exchange business and prior-period reserve development were favorable. Investors should note that the GAAP-to-adjusted gap remains wide due to roughly $2.0 billion of annual intangible amortization and that the litigation charges are not final, since both matters are subject to appeal and penalty determinations.
The announced Rite Aid prescription file and store acquisitions and the new CFO and CMO hires are additional items to monitor. The filing is an 8-K furnishing the earnings press release under Item 2.02 and is not deemed filed for Exchange Act liability purposes.
02—Key points
Key Highlights
- Total revenues rose 8.4% to $98.9 billion, with growth across all operating segments; six-month revenues reached $193.5 billion.
- GAAP diluted EPS fell to $0.80 from $1.41 due to $833 million in legacy litigation charges ($542 million Omnicare False Claims Act penalties and $291 million PBM reporting judgment), while Adjusted EPS was steady at $1.81 versus $1.83.
- Full-year 2025 Adjusted EPS guidance raised to $6.30–$6.40 from $6.00–$6.20; GAAP diluted EPS guidance lowered to $3.84–$3.94 from $4.23–$4.43.
- Operating cash flow guidance raised to at least $7.5 billion from about $7.0 billion, though first-half operating cash flow declined to $6.5 billion from $8.0 billion.
- Health Care Benefits adjusted operating income jumped 39.4% to $1.31 billion, but MBR rose to 89.9% from 89.6% after a $471 million Group Medicare Advantage premium deficiency reserve; medical membership fell 358,000 sequentially to 26.7 million.
- Health Services adjusted operating income declined 17.8% to $1.58 billion on pharmacy client price concessions and higher health care delivery costs, while Pharmacy & Consumer Wellness adjusted operating income rose 7.6% to $1.34 billion on prescription volume growth.
- CVS agreed to acquire prescription files and certain stores from Rite Aid, and announced a $20.0 billion ten-year commitment to simplify the U.S. health system.
03—Questions
Frequently Asked Questions
Why did GAAP earnings fall sharply while adjusted earnings held steady?
GAAP diluted EPS dropped to $0.80 from $1.41 mainly because of $833 million in legacy litigation charges recorded in Q2 2025 tied to two court decisions over past business practices. CVS excludes these charges, along with intangible amortization, from Adjusted EPS, which therefore remained near $1.81 versus $1.83 a year earlier. Investors should weigh whether such charges recur, since the company treats them as non-ordinary-course items.
What changed in full-year 2025 guidance?
Adjusted EPS guidance was raised to $6.30–$6.40 from $6.00–$6.20, and operating cash flow guidance was raised to at least $7.5 billion from about $7.0 billion. GAAP diluted EPS guidance was lowered to $3.84–$3.94 from $4.23–$4.43, reflecting the litigation charges and other non-GAAP adjustments of roughly $1.22 billion in legacy litigation charges and $2.0 billion in intangible amortization.
Are the litigation charges final, and could more follow?
Not necessarily. The Omnicare False Claims Act verdict is subject to entry of judgment and an appeal the company intends to pursue, and the PBM remuneration judgment will not be final until penalties are set by the court; CVS also intends to appeal it. Additional amounts could therefore change as these matters progress.
What is driving pressure in Health Care Benefits and Health Services?
In Health Care Benefits, the MBR rose 30 basis points to 89.9% because of a $471 million premium deficiency reserve on Group Medicare Advantage, partly offset by favorable individual exchange risk adjustment. In Health Services, adjusted operating income fell 17.8% due to continued pharmacy client price improvements and higher costs in the health care delivery business, partly offset by better purchasing economics.
What is the significance of the Rite Aid transaction?
CVS Pharmacy agreed to acquire prescription files from certain Rite Aid pharmacies across 15 states where CVS operates, and to acquire and operate certain Rite Aid stores in Idaho, Oregon and Washington. The closings are underway but remain subject to customary conditions. The filing does not quantify the purchase price or expected financial impact, so investors should look to management commentary for sizing.
04—Continue